Pituitary最新文献

{"title":"Good response rates and predictors during the first year of cabergoline treatment in large invasive prolactinomas.","authors":"Hayri Bostan, Bekir Ucan, Hakan Duger, Sema Hepsen, Serdar Kayihan, Alper Dilli, Ilknur Ozturk Unsal, Erman Cakal, Muhammed Kizilgul","doi":"10.1007/s11102-025-01512-5","DOIUrl":"https://doi.org/10.1007/s11102-025-01512-5","url":null,"abstract":"<p><strong>Purpose: </strong>The factors predicting the long-term response to cabergoline are not well known, particularly in more invasive prolactinomas. This study aimed to evaluate the rate of good response (GR) (normoprolactinemia and ≥ 50% tumor shrinkage) at the one-year follow-up and to identify predictors of GR in patients with large invasive prolactinomas.</p><p><strong>Methods: </strong>This retrospective single-center study included 38 patients (32 males, 6 females; mean age 41.9 ± 12.8 years) with invasive macroprolactinomas (baseline median prolactin: 2530 (1726-5451) ng/mL, mean longest tumor diameter: 36.4 ± 12.8 mm) who were followed for at least one year under cabergoline therapy. Prolactin levels and tumor volume changes were analyzed at early and late follow-ups. Patients were classified as good responders (GRs) or poor responders (PRs) based on their first-year outcomes.</p><p><strong>Results: </strong>At the first year, 17 patients (44.7%) achieved a GR. Baseline parameters were comparable between groups, but GRs had significantly higher normoprolactinemia rates (70.6% vs. 23.8%,p = 0.004) and greater tumor shrinkage (57.3 ± 15.6% vs. 41.9 ± 21.9%,p = 0.02) at 3-6 months. An early tumor shrinkage cut-off rate of 44.9% (88% sensitivity, 62% specificity) or an early prolactin cut-off level of 30 ng/mL (75% sensitivity, 77% specificity) were identified as good predictors of GR in the first-year. All GRs maintained normoprolactinemia and ≥ 50% tumor shrinkage, while 33.3% and 42.9% of PRs failed to meet these goals, respectively, at the last visit (p = 0.009, p = 0.002). Three of PRs required surgery during follow-up.</p><p><strong>Conclusions: </strong>Approximately half of invasive prolactinoma patients achieved the composite goal within one year of cabergoline therapy. Early follow-up studies, rather than baseline characteristics, are strong predictors of treatment success.</p>","PeriodicalId":20202,"journal":{"name":"Pituitary","volume":"28 2","pages":"38"},"PeriodicalIF":3.3,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143597648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of endoscopic endonasal surgery for pediatric craniopharyngioma with a focus on morphological preservation of the pituitary stalk and endocrine functions.","authors":"Hiroyoshi Kino, Hiroyoshi Akutsu, Shuho Tanaka, Atsushi Iwabuchi, Takuma Hara, Yusuke Morinaga, Takeshi Hongo, Kotaro Osawa, Shingo Takano, Eiichi Ishikawa","doi":"10.1007/s11102-025-01506-3","DOIUrl":"https://doi.org/10.1007/s11102-025-01506-3","url":null,"abstract":"<p><strong>Purpose: </strong>Preservation of endocrine function in pediatric patients with craniopharyngioma is crucial. However, few reports of endoscopic endonasal surgery (EES) for pediatric craniopharyngiomas with intending endocrine function preservation exist. This study aimed to identify the outcomes of EES with intending preservation of pituitary stalk in pediatric patients with craniopharyngioma.</p><p><strong>Methods: </strong>Data from 22 pediatric patients with craniopharyngioma who underwent 35 EESs between 2011 and 2022 were retrospectively assessed. The tumor location (infradiaphragmatic [ID] or supradiaphragmatic [SD]) and endocrine functions were evaluated. The patients were divided into two groups: those with preoperatively preserved some endocrine function (Group P) and already completely lost endocrine function (Group ACL). Morphological preservation of the pituitary stalk (MPPS) and postoperative endocrine functional outcomes were analyzed only in the cases of Group P. Tumor recurrence was evaluated in all patients.</p><p><strong>Results: </strong>In the 35 EESs, the tumors were ID in 17 cases and SD in 18. Twenty-five cases were included in Group P and 10 in Group ACL. In Group P, MPPS was achieved in 18 (72%) cases, and postoperative preservation of some endocrine function was achieved in 14 (77.8%) of the MPPS cases. ID tumor (P < 0.001) and intraoperative MPPS (P < 0.001) were associated with postoperative preservation of some endocrine function. Intraoperative MPPS (P = 0.044) was a significantly associated risk factor for tumor recurrence.</p><p><strong>Conclusions: </strong>In EES for pediatric craniopharyngiomas, postoperative preservation of some endocrine function is achievable in ID tumors with MPPS. Therefore, preservation of endocrine function should be attempted in cases of ID tumors. However, clinicians should be aware that MPPS increases the risk of tumor recurrence.</p>","PeriodicalId":20202,"journal":{"name":"Pituitary","volume":"28 2","pages":"34"},"PeriodicalIF":3.3,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143557753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying research priorities for pituitary adenoma surgery: an international Delphi consensus statement.","authors":"Nicola Newall, Alexandra Valetopoulou, Danyal Z Khan, Anouk Borg, Pierre M G Bouloux, Fion Bremner, Michael Buchfelder, Simon Cudlip, Neil Dorward, William M Drake, Juan C Fernandez-Miranda, Maria Fleseriu, Mathew Geltzeiler, Joy Ginn, Mark Gurnell, Steve Harris, Zane Jaunmuktane, Márta Korbonits, Michael Kosmin, Olympia Koulouri, Hugo Layard Horsfall, Adam N Mamelak, Richard Mannion, Pat McBride, Ann I McCormack, Shlomo Melmed, Katherine A Miszkiel, Gerald Raverot, Thomas Santarius, Theodore H Schwartz, Inma Serrano, Gabriel Zada, Stephanie E Baldeweg, Angelos G Kolias, Hani J Marcus","doi":"10.1007/s11102-025-01502-7","DOIUrl":"10.1007/s11102-025-01502-7","url":null,"abstract":"<p><strong>Purpose: </strong>Pituitary surgery is the mainstay treatment for most pituitary adenomas, but many questions remain about perioperative and long-term management and outcomes. This study aimed to identify the most pressing research priorities in pituitary surgery with input from patients, caregivers, and healthcare professionals.</p><p><strong>Methods: </strong>An initial survey of patients, caregivers, and healthcare professionals assembled priorities related to preoperative care, surgical techniques, and postoperative management in pituitary surgery. Priorities were thematically grouped into summary priorities, and those answered by existing evidence were omitted following a literature review. An interim survey asked patients, caregivers, and healthcare professionals to select their top 10 priorities from the remaining list. The highest-ranked priorities advanced to a consensus meeting, where the top 10 questions were prioritized.</p><p><strong>Results: </strong>In the initial survey, 147 participants-60.5% of whom were patients, caregivers, or patient support group representatives-submitted 785 priorities, which were then condensed into 52 summary priorities. After a literature review, 33 unanswered priorities were included in the interim survey, completed by 155 respondents, of whom 54.2% were patients, caregivers, or patient support group representatives. The top-ranked priorities were discussed by 14 participants (7 patients and 7 healthcare professionals) during a consensus meeting. The top 10 priorities covered a variety of themes including enhancing diagnosis and management of pituitary adenomas, advancing surgical techniques and technologies, optimizing the prediction of outcomes and complications, and improving patient support and follow-up.</p><p><strong>Conclusions: </strong>The top 10 research priorities in pituitary surgery aim to align researchers and direct funding in order to maximize impact and champion patient representation.</p>","PeriodicalId":20202,"journal":{"name":"Pituitary","volume":"28 2","pages":"36"},"PeriodicalIF":3.3,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11882698/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143557750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dopamine agonists and weight changes in prolactinoma patients.","authors":"Nicholas Contento, David A Paul, G Edward Vates, Brent Johnson, Zachary Brehm, Ismat Shafiq","doi":"10.1007/s11102-025-01510-7","DOIUrl":"https://doi.org/10.1007/s11102-025-01510-7","url":null,"abstract":"<p><strong>Purpose: </strong>Prolactinomas, the predominant pituitary adenoma type, are primarily treated with dopamine agonists to decrease prolactin levels and tumor size. The use of dopamine agonists has been shown to improve metabolic parameters and lead to weight loss in prolactinoma patients. However, the data is conflicting and sparse. In the current study, we aim to review weight variations in prolactinoma patients treated with dopamine agonists.</p><p><strong>Methods: </strong>We identified prolactinoma patients referred to one pituitary clinic between 2010 and 2020. Data from prolactinoma patients treated with dopamine agonist therapy were retrospectively collected over the span of 1 year. Serum prolactin and weight measurements were obtained at the time of diagnosis and at 3-months, 6-months, and 12-month time points. We also collected information on the patient's age, sex, BMI, diabetes history, and dopamine agonist treatment regimen.</p><p><strong>Results: </strong>91 patients with prolactinoma treated with dopamine agonist were included in the study. Among the 91 patients, 47 were females and 44 were males. The average age for females was 30.5 years and for males were 49 years. The average BMI in females was 31.02 kg/m² and in men were 31.05 kg/m². The prolactin level at baseline was higher in men with an average of 779.95 ng/ml while in females' initial prolactin levels were 433 ng/ml. Prolactin levels decreased to normal levels as dopamine agonist treatment was continued over the course of one year, with the most precipitous drop occurring between 0 and 3 months. While prolactin levels at baseline were higher in men, prolactin levels in men dropped on average 644 ng/mL over the 0-3-month period, compared to the 257 ng/mL average drop in women. While not significant, patients overall lost weight over the treatment period, with men losing on average 7.8 pounds and women losing 1.1 pound.</p><p><strong>Conclusions: </strong>The use of dopamine agonists for a duration of about 12 months did not result in statistically significant weight loss among patients with prolactinoma.</p>","PeriodicalId":20202,"journal":{"name":"Pituitary","volume":"28 2","pages":"35"},"PeriodicalIF":3.3,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143557748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term clinical outcome of 103 patients with acromegaly after pituitary surgery.","authors":"Anna Pennlund, Daniela Esposito, Thomas Olsson Bontell, Thomas Skoglund, Tobias Hallén, Helena Carén, Gudmundur Johannsson, Daniel S Olsson","doi":"10.1007/s11102-025-01503-6","DOIUrl":"10.1007/s11102-025-01503-6","url":null,"abstract":"<p><strong>Purpose: </strong>Acromegaly is a rare disease that can be challenging to treat due to residual pituitary adenoma after surgery or variable response to medical treatments. The primary aim of the study was to evaluate the path of treatment and long-term outcome of acromegaly after pituitary surgery.</p><p><strong>Methods: </strong>Patients with acromegaly who had undergone surgery for a growth hormone-producing pituitary neuroendocrine tumor also known as a pituitary adenoma, at Sahlgrenska University Hospital between 1994 and 2019 were included in the study. Medical records from diagnosis to the end of study (November 2022) were reviewed for surgical outcome and treatment patterns related to acromegaly.</p><p><strong>Results: </strong>In the cohort of 103 patients, 111 surgeries were performed. Mean follow-up duration was 12.7 (range: 0-37) years. Lesions were identified as a macroadenoma in 76 (76.8%) cases. At post-surgical follow-up until discharge from hospital, surgical complications and new pituitary hormone deficiency or syndrome of inappropriate antidiuretic hormone secretion occurred in 37% of cases. At 1-year post-surgery follow-up, 50% of evaluable patients achieved biochemical control of acromegaly. Of the 96 patients who had follow-up > 1 year, 53 (51.5%) had no additional medication for acromegaly after surgery until end of their follow-up. From diagnosis to the end of follow-up, 53 patients received medical therapy and seven were treated with radiotherapy.</p><p><strong>Conclusion: </strong>About half of the patients had biochemical control of acromegaly 1-year post-surgery. Treatment patterns reflected the complexity of post-surgical management and provided an overview of the long-term clinical progression in patients with acromegaly following pituitary surgery.</p>","PeriodicalId":20202,"journal":{"name":"Pituitary","volume":"28 2","pages":"33"},"PeriodicalIF":3.3,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11846723/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143477082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and risk of complications in untreated patients with adult growth hormone deficiency.","authors":"Hidenori Fukuoka, Takaaki Endo, Satoshi Tsuboi, Shingo Fujio","doi":"10.1007/s11102-025-01500-9","DOIUrl":"10.1007/s11102-025-01500-9","url":null,"abstract":"<p><strong>Purpose: </strong>Adult growth hormone deficiency (AGHD) increases the prevalence of complications, including metabolic disorder, leading to increased cardiovascular mortality from cardiovascular diseases. However, no large database studies have evaluated AGHD patients without GH replacement therapy (GHRT). We investigated the prevalence of AGHD-related complications in patients without GHRT.</p><p><strong>Methods: </strong>Patients with AGHD and associated complications were identified from the Medical Data Vision claims database using Japanese local disease codes mapped to ICD-10 codes. The prevalence of AGHD-related complications in 2020 was estimated to compare with the prevalence in the Japanese general population in the latest available year 2020. Risk factors for complications were evaluated by Kaplan-Meier curves and a Cox proportional hazard model.</p><p><strong>Results: </strong>We identified 8,809 untreated patients with AGHD from April 2008 to September 2022, including 3,430 in 2020. In 2020, the prevalence of complications was higher in the AGHD population adjusted for sex and age than in the Japanese general population, e.g., diabetes mellitus, 9.3% vs. 3.6%; osteoporosis, 4.8% vs. 1.3%; and dyslipidemia, 22.0% vs. 3.9%. Age was a significant risk factor for most complications, and female sex for osteoporosis. Diabetes mellitus was a significant risk factor for dyslipidemia, ischemic heart disease, cerebrovascular disease, and all-cause death.</p><p><strong>Conclusion: </strong>Untreated patients with AGHD have a higher prevalence of metabolic complications than the general population despite no difference in their related risk factors. Given the low use of GHRT in this study, comprehensive treatment approaches that include GHRT need to be considered to alleviate the risk of complications.</p>","PeriodicalId":20202,"journal":{"name":"Pituitary","volume":"28 2","pages":"32"},"PeriodicalIF":3.3,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11836217/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143449938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Headache in pituitary adenomas: frequency, characteristics and outcome after treatment.","authors":"Cristiane R Scaf, Ananda Altoé, Nina Ventura, Maurice Vincent, Leandro Kasuki, Mônica R Gadelha","doi":"10.1007/s11102-025-01504-5","DOIUrl":"https://doi.org/10.1007/s11102-025-01504-5","url":null,"abstract":"<p><strong>Introduction: </strong>Headache is common among patients diagnosed with pituitary adenoma (PA). There are still controversies regarding the headache presentation, pathophysiology and outcome after treatment in these patients.</p><p><strong>Objectives: </strong>To determine the prevalence of headache among patients with PA, describe their phenotypes and identify precipitating factors. Also, to evaluate prospectively if PA treatment leads to headache improvement.</p><p><strong>Methods: </strong>Treatment-naïve adult patients with PA were included. A questionnaire based on the beta version of the International Classification of Headache Disorders 3rd edition was created to classify the headaches. Patients submitted to surgery or medical treatment were reevaluated at least three to six months after treatment.</p><p><strong>Results: </strong>Headache during the previous 3 months was present in 62% of the 104 patients. The most prevalent phenotypes were migraine and tension-type headache. Trigeminal autonomic cephalalgias (TACs) were observed only in prolactinoma patients. Both genders presented headache at similar rates (64% in females and 58% in males) but patients with headache were younger (41.5 ± 13.8 vs. 56.8 ± 13.6 years). Tumor characteristics were not determinant of headache. Patients with acromegaly that presented headache had higher GH levels. Headache was more frequent in prolactinomas (83%) than in NFPA (52%). After disease remission or control, resolution of headache was observed in 83%, 50% and 33% of the NFPA, somatotropinomas and prolactinomas, respectively.</p><p><strong>Conclusions: </strong>Migraine and tension-type are the most common headache phenotypes in PA patients, and TACs were only observed in prolactinomas. Also, headache was more common in prolactinomas than in NFPA. GH levels were higher in patients with acromegaly that presented headache. Surgical and medical treatments completely resolve the headaches in 50% of the patients.</p>","PeriodicalId":20202,"journal":{"name":"Pituitary","volume":"28 2","pages":"31"},"PeriodicalIF":3.3,"publicationDate":"2025-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143383249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to letter to the editor \"Hypopituitarism and COVID-19, what else?\"","authors":"Giulia Carosi, Giovanna Mantovani, Luigi Di Filippo, Andrea Giustina","doi":"10.1007/s11102-025-01499-z","DOIUrl":"10.1007/s11102-025-01499-z","url":null,"abstract":"","PeriodicalId":20202,"journal":{"name":"Pituitary","volume":"28 1","pages":"29"},"PeriodicalIF":3.3,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143123116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hospital frailty risk score predicts postoperative outcomes after endoscopic endonasal resection of non-functioning pituitary adenomas.","authors":"Foad Kazemi, Jiaqi Liu, Megan Parker, Adrian E Jimenez, A Karim Ahmed, Roberto Salvatori, Amir H Hamrahian, Nicholas R Rowan, Murugappan Ramanathan, Nyall R London, Masaru Ishii, Jordina Rincon-Torroella, Gary L Gallia, Debraj Mukherjee","doi":"10.1007/s11102-024-01496-8","DOIUrl":"10.1007/s11102-024-01496-8","url":null,"abstract":"<p><strong>Purpose: </strong>Frailty indices are invaluable resources in risk stratification and predicting high-value care outcomes for neurosurgical patients. The Hospital Frailty Risk Score (HFRS) is a recently developed and validated method for evaluating frailty; however, its implementation has yet to be assessed in patients with non-functioning pituitary adenomas undergoing endoscopic endonasal resection. In this study, we aimed to evaluate HFRS's predictive ability for high-value care outcomes, namely postoperative complications, length of stay (LOS), and hospital charges, and to compare it to other traditionally used frailty indices.</p><p><strong>Methods: </strong>A retrospective review of electronic medical records from 2017 to 2020. A total of 109 ICD-10 codes corresponding to various frailty-related conditions were used to identify the components of HFRS. These components were then used to calculate the HFRS for each patient, with higher scores indicative of elevated frailty. Standard multivariate logistic regression models were employed to explore the association between HFRS and high-value care outcomes. Model discrimination was assessed using the area under the ROC curves, and the DeLong test was used to compare AUCs.</p><p><strong>Results: </strong>A total of 172 patients were included, with a mean age of 57.27 ± 12.95 years and an average HFRS score of 3.65 <math><mo>±</mo></math> 3.27. Among patients, 56% were male, 5.2% experience postoperative complications, 23.3% endured extended LOS, 25.0% incurred high hospital charges. In multivariate regression models, greater HFRS was significantly and independently associated with postoperative complications (OR = 1.51, P < 0.001), extended LOS (OR = 1.17, P = 0.006) and high hospital charges (OR = 1.18, P = 0.004). HFRS had the highest AUC compared to other frailty indices and was the most parsimonious model, with AUC values of 0.82, 0.64, and 0.63 for predicting complications, extended LOS, and higher charges, respectively.</p><p><strong>Conclusion: </strong>Higher HFRS scores are significantly associated with postoperative complications, prolonged LOS, and high hospital charges for patients undergoing pituitary surgery.</p>","PeriodicalId":20202,"journal":{"name":"Pituitary","volume":"28 1","pages":"27"},"PeriodicalIF":3.3,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of sarcopenic obesity in patients with acromegaly.","authors":"Claudia Pinheiro Sanches Rocha, Natália Nachbar Hupalowski, Vicente Florentino Castaldo Andrade, Cesar Luiz Boguszewski, Victória Zeghbi Cochenski Borba","doi":"10.1007/s11102-024-01494-w","DOIUrl":"10.1007/s11102-024-01494-w","url":null,"abstract":"<p><strong>Purpose: </strong>Sarcopenic obesity (SO), a condition characterized by the coexistence of obesity and sarcopenia, has primarily been studied in elderly populations. However, it can also affect individuals with chronic diseases. This study aims to evaluate the prevalence of SO in patients with acromegaly.</p><p><strong>Methods: </strong>Observational, cross-sectional study, involving patients with acromegaly followed at a tertiary center and controls matched for age and sex. Health assessment questionnaire, physical tests, body composition and bone mineral density assessment, were performed in all participants. SO was diagnosed using criteria from ESPEN and EASO Consensus Statements.</p><p><strong>Results: </strong>48 patients with acromegaly (acromegaly group - AG, 26 women, mean age 56.3 ± 11.6, mean BMI 31.3 ± 4.9) were compared to 48 controls (control group - CG, 26 women, mean age 56.7 ± 13.7, BMI 25.5 ± 4.7). Despite having greater total and appendicular lean mass, AG showed significant impairments in physical performance, particularly in strength, gait speed and balance (p < 0.05). The prevalence of SO in the AG was 16.7%, compared to 0% in the CG (p = 0.006), and positively correlated with increased fat mass and impaired physical performance.</p><p><strong>Conclusions: </strong>SO is present in patients with acromegaly and is associated with notable functional impairments despite increased muscle mass.</p>","PeriodicalId":20202,"journal":{"name":"Pituitary","volume":"28 1","pages":"25"},"PeriodicalIF":3.3,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}